EZH2 and prostate cancer: Studies also found frequent mutations in the EZH2 SET domain [for example, tyrosine residue 646 (Y646)] and EZH2 somatic mutations in various tumors such as germinal center (GC) diffuse large B-cell lymphoma (DLBCL), non-small cell lung cancer, prostate cancer, and colon carcinoma (20).